CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.

Shares of GSK PLC GSK rose 1.02% to £14.30 Wednesday, on what proved to be an all-around positive trading session for the ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

GSK (GSK) stock gains as FDA broadens the label for the company's asthma therapy Nucala l for COPD with an eosinophilic ...

GSK’s blockbuster respiratory drug Nucala was approved Thursday for certain patients with chronic obstructive pulmonary ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...

GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

The film tells the story of a family impacted by the disease and shares the importance of checking to make sure that children ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...